Amgen Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - General · United States
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-03-10$327.36 RISE2025-05-14$262.28 PEAK2025-07-23$309.22 135d | -19.9% 65d | Missed | Missed | — | — | +17.9% 70d | Missed |
DROP2024-09-20$337.38 RISE2025-01-06$258.59 PEAK2025-03-10$327.36 171d | -23.4% 108d | Missed | Missed | — | — | +26.6% 63d | Missed |
DROP2024-02-01$324.56 RISE2024-04-18$262.75 PEAK2024-07-16$333.14 166d | -19.0% 77d | Missed | Missed | — | — | +26.8% 89d | Missed |
DROP2023-01-23$260.97 RISE2023-06-01$214.27 PEAK2023-08-15$266.01 204d | -17.9% 129d | Missed | Missed | — | — | +24.1% 75d | Missed |
DROP2021-07-23$247.72 RISE2021-11-30$198.88 PEAK2022-02-08$241.01 200d | -19.7% 130d | Missed | Missed | — | — | +21.2% 70d | Missed |
DROP2020-07-20$260.95 RISE2020-10-28$216.38 PEAK2021-01-26$258.60 190d | -17.1% 100d | Missed | Missed | — | — | +19.5% 90d | Missed |
DROP2020-01-15$241.70 RISE2020-03-12$182.24 PEAK2020-05-11$242.74 117d | -24.6% 57d | Missed | Missed | — | — | +33.2% 60d | Missed |
Merck & Co. has surged past the S&P 500 Index over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.
Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...
Pharmaceutical companies have spent years targeting a common blood particle associated with heart-attack risks.
NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.
RTX builds a $271B backlog on defense demand and recovering air travel, but tariffs and supply-chain issues cloud growth.
The Dow gave back its opening gains, with healthcare stocks a big drag. The blue-chip index was trading flat, while the S&P 500 was up 0.9%, and the Nasdaq rose 1.4%. UnitedHealth Group and Amgen, among the Dow's top five stocks, were down by nearly 3% and 0.4%, respectively.
(Bloomberg) -- Quantinuum Inc., a quantum computing company backed by Honeywell International Inc., is seeking to raise $1.05 billion in its US initial public offering, capitalizing on investor enthusiasm for the technology. Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarRussia Tells US to Evacuate Its Diplomats and Citizens From KyivUS Strikes Targets in Iran Even as Trump Hails Progress on DealPutin Signs Law on Use of Army to Aid Russians Detained Abro
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
The Dow is no longer dominated by industrial, energy, manufacturing, and consumer goods companies.
The Dow is no longer dominated by industrial, energy, manufacturing, and consumer goods companies.
Amgen Inc. (NASDAQ:AMGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Amgen announced the retirement of its Executive Vice President and Chief Financial Officer, Peter Griffith, who has held the role since 2020. During his tenure, Griffith was instrumental in strengthening the company’s financial position, supporting capital allocation, and […]
Amgen Inc. (NASDAQ:AMGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Amgen announced the retirement of its Executive Vice President and Chief Financial Officer, Peter Griffith, who has held the role since 2020. During his tenure, Griffith was instrumental in strengthening the company’s financial position, supporting capital allocation, and […]
Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.
Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.
Amgen names a new chief financial officer, Thales hires Nissan’s former CFO and Rent the Runway’s finance chief tenders his resignation.
Amgen names a new chief financial officer, Thales hires Nissan’s former CFO and Rent the Runway’s finance chief tenders his resignation.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AMGN | +2.11% | -12.68% | +2.90% | +16.87% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -0.86% | -6.97% | +6.34% | +4.18% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 30.55M | $10.75B | 0.37% | Unchanged | 2026-03-31 |
| CapResearch | fundamental | 6.96M | $2.45B | 0.38% | Added+49.6% | 2026-03-31 |
| FidelityFMR | fundamental | 3.78M | $1.33B | 0.07% | Added+5.1% | 2026-03-31 |
| Wellington | fundamental | 228.0K | $80.23M | 0.01% | Trimmed-15.6% | 2026-03-31 |
| DEShaw | quant | 178.0K | $62.63M | 0.04% | Added+514.3% | 2026-03-31 |
| TwoSigma | quant | 71.7K | $25.22M | 0.02% | Trimmed-89.8% | 2026-03-31 |
| Bridgewater | macro | 14.8K | $5.20M | 0.02% | Added+389.2% | 2026-03-31 |
| TRowePrice | fundamental | 1.87M | $656.97K | 0.08% | Added+78.9% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | Austin Wanda M | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | Drake Michael V | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | Druker Brian | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | ECKERT ROBERT | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | Garland Greg C. | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | HOLLEY CHARLES M | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | ISHRAK OMAR | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | Jacks Tyler | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | Klotman Mary E. | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | Kullman Ellen Jamison | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-21 | MILES AMY E | Director | A Grant / award | 665 | — | +$0 |
| 2026-05-11 | Bradner James E. | EVP, Research and Development | F Tax withholding | 446 | $331.11 | −$147.7K |
| 2026-05-11 | Bradway Robert A | Chairman, CEO and President | F Tax withholding | 2,079 | $331.11 | −$688.4K |
| 2026-05-11 | Gordon Murdo | EVP, Global Commercial Ops | F Tax withholding | 615 | $331.11 | −$203.6K |
| 2026-05-11 | Graham Jonathan P | EVP & Gen. Counsel & Sec. | F Tax withholding | 499 | $331.11 | −$165.2K |
| 2026-05-11 | Griffith Peter H. | EVP & CFO | F Tax withholding | 556 | $331.11 | −$184.1K |
| 2026-05-11 | Grygiel Nancy A. | SVP & CCO | F Tax withholding | 88 | $331.11 | −$29.1K |
| 2026-05-11 | Khosla Rachna | SVP, Business Development | F Tax withholding | 93 | $331.11 | −$30.8K |
| 2026-05-11 | Miller Derek | SVP, Human Resources | F Tax withholding | 151 | $331.11 | −$50.0K |
| 2026-05-11 | REESE DAVID M | EVP & Chief Technology Officer | F Tax withholding | 556 | $331.11 | −$184.1K |
| 2026-05-11 | Santos Esteban | EVP, Operations | F Tax withholding | 522 | $331.11 | −$172.8K |
| 2026-05-11 | Busch Matthew C. | VP, Finance & CAO | F Tax withholding | 41 | $331.11 | −$13.6K |
| 2026-05-07 | Drake Michael V | Director | A Grant / award | 80 | — | +$0 |
| 2026-05-07 | HOLLEY CHARLES M | Director | A Grant / award | 129 | — | +$0 |
| 2026-05-07 | ISHRAK OMAR | Director | A Grant / award | 106 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | 5.59 | — | — |
| 2026-04-30 | 4.77 | 5.15 | +8.04% |
| 2026-02-03 | 4.73 | 5.29 | +11.94% |
| 2025-11-04 | 5.01 | 5.64 | +12.47% |
| 2025-08-05 | 5.28 | 6.02 | +14.08% |
| 2025-05-01 | 4.26 | 4.90 | +15.01% |
| 2025-02-04 | 5.08 | 5.31 | +4.63% |
| 2024-10-30 | 5.11 | 5.58 | +9.29% |
| 2024-08-06 | 5.00 | 4.97 | -0.62% |
| 2024-05-02 | 3.89 | 3.96 | +1.83% |
| 2024-02-06 | 4.59 | 4.71 | +2.58% |
| 2023-10-31 | 4.68 | 4.96 | +5.90% |
| 2023-08-03 | 4.49 | 5.00 | +11.27% |
| 2023-04-27 | 3.85 | 3.98 | +3.27% |
| 2023-01-31 | 4.09 | 4.09 | -0.03% |
| 2022-11-03 | 4.45 | 4.70 | +5.61% |